The study, by scientists at AgeX and BioTime, in collaboration with Baltimore, Maryland-based bioinformatics company Insilico Medicine, utilized artificial intelligence technology to parse millions of gene expression data points to decipher the complex mechanisms controlling natural tissue regeneration.
The results showed that the candidate genes are expressed differently in tissues early in development when they are capable of regeneration compared to later in life when regeneration can no longer take place.
Some of the genes, including one highlighted in the study, COX7A1, displayed a rare profile of being nearly universally dysregulated in diverse types of cancer.
The discoveries may lead to novel strategies to induce tissue regeneration in the context of trauma or age-related degenerative disease, as well as treat and diagnose cancer.
AgeX Therapeutics applies technology relating to cellular immortality and regenerative biology to aging and age-related diseases. The company has three initial areas of product development: pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial planned indications for these products are Type 2 diabetes, cardiac ischemia, and tissue regeneration respectively.
BioTime is focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent cells and cell/drug delivery.
Insilico Medicine applies next-generation artificial intelligence technology to drug discovery and aging research.
The company pursues internal drug discovery programmes in cancer, Parkinson's, Alzheimer's, sarcopenia, and geroprotector discovery, and provides services to pharmaceutical companies.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes